10-86691921-G-A
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_007078.3(LDB3):c.715G>A(p.Val239Ile) variant causes a missense change. The variant allele was found at a frequency of 0.0000917 in 1,614,132 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V239A) has been classified as Uncertain significance.
Frequency
Consequence
NM_007078.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
LDB3 | NM_007078.3 | c.715G>A | p.Val239Ile | missense_variant | 6/14 | ENST00000361373.9 | |
LDB3 | NM_001368067.1 | c.574G>A | p.Val192Ile | missense_variant | 7/9 | ENST00000263066.11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
LDB3 | ENST00000361373.9 | c.715G>A | p.Val239Ile | missense_variant | 6/14 | 1 | NM_007078.3 | P4 | |
LDB3 | ENST00000263066.11 | c.574G>A | p.Val192Ile | missense_variant | 7/9 | 1 | NM_001368067.1 |
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152172Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000135 AC: 34AN: 251428Hom.: 0 AF XY: 0.000103 AC XY: 14AN XY: 135894
GnomAD4 exome AF: 0.0000917 AC: 134AN: 1461842Hom.: 0 Cov.: 32 AF XY: 0.000100 AC XY: 73AN XY: 727220
GnomAD4 genome AF: 0.0000919 AC: 14AN: 152290Hom.: 0 Cov.: 33 AF XY: 0.0000672 AC XY: 5AN XY: 74460
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:1Other:1
Uncertain significance, criteria provided, single submitter | research | Biesecker Lab/Clinical Genomics Section, National Institutes of Health | Jun 24, 2013 | - - |
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | Variant interpretted as Uncertain significance and reported on 01-06-2017 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Sep 01, 2020 | This variant is associated with the following publications: (PMID: 23861362) - |
Myofibrillar myopathy 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 192 of the LDB3 protein (p.Val192Ile). This variant is present in population databases (rs201417512, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with LDB3-related conditions. ClinVar contains an entry for this variant (Variation ID: 191697). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 29, 2023 | The p.V239I variant (also known as c.715G>A), located in coding exon 5 of the LDB3 gene, results from a G to A substitution at nucleotide position 715. The valine at codon 239 is replaced by isoleucine, an amino acid with highly similar properties. This alteration (described as NM_001080116.1:c.574G>A p.V192I) has been reported as a secondary cardiac variant in an exome cohort (Ng D et al. Circ Cardiovasc Genet, 2013 Aug;6:337-46). This variant has also been reported in a sudden death case (described as NM_001171610 c.919G>A p.V307I) and a hypertrophic cardiomyopathy (HCM) case; however, both individuals had co-occurring variants and limited clinical details (Hertz CL et al. Int J Legal Med, 2016 Jan;130:91-102; van Lint FHM et al. Neth Heart J, 2019 Jun;27:304-309). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at